安徽省药监局发文:严管药店处方药销售

2019-02-19 夕语 据安徽省药监局整理

节后,刚刚上班,药店经理人推送了一篇《药监不放假,加班查药店!5大重点需注意》的文章,预估接下来药店处方药销售将迎来最严管制。 果然,这场行动如约而至,就在18日,安徽省药监局发布了《关于进一步加强药品零售企业处方药销售管理的通知》(以下简称《通知》),要求全省各级药品监管部门将本《通知》精神及时传达到辖区每一家药品零售企业,督促企业严格落实主体责任。


节后,刚刚上班,一篇《药监不放假,加班查药店!5大重点需注意》的文章,预估接下来药店处方药销售将迎来最严管制。

果然,这场行动如约而至,就在18日,安徽省药监局发布了《关于进一步加强药品零售企业处方药销售管理的通知》(以下简称《通知》),要求全省各级药品监管部门将本《通知》精神及时传达到辖区每一家药品零售企业,督促企业严格落实主体责任。

该《通知》还要求,药品监管部门要结合GSP认证跟踪检查、专项检查、日常监督检查等工作,进一步加强监管。对在检查中发现执业药师不在岗履职或零售药店不凭处方销售处方药的,依据《药品流通监督管理办法》第38条规定,按从重情节进行严肃查处。

《通知》指出,为加强全省药品零售企业的监督管理,有效防控风险,保障公众用药安全,药品零售企业必须严格执行药品分类管理规定。

第一、药品零售企业禁止销售麻醉药品、一类精神药品、终止妊娠药品、蛋白同化制剂、肽类激素(胰岛素除外)、药品类易制毒化学品、放射性药品、疫苗及法律法规规定的其它不得经营的药品。对限量销售的品种,必须符合相关规定要求。

第二、药品零售企业须按核准的经营范围和方式凭处方销售注射剂、医疗用毒性药品、第二类精神药品、精神障碍治疗药(抗精神病、抗焦虑、抗躁狂、抗抑郁药)、抗病毒药(逆转录酶抑制剂和蛋白酶抑制剂)、肿瘤治疗药、含麻醉药品的复方口服溶液和曲马多制剂、列入处方药目录的含麻黄碱类复方制剂、未列入非处方药目录的抗菌药和激素、国家法律法规规定的其他必须凭处方销售的品种。

第三、处方药不得开架销售。药品零售企业必须按照《药品经营质量管理规范》的要求,做好处方药和非处方药的分区陈列,并贴有专有标识。处方药不得采用开架自选的方式陈列和销售。不得以搭售、买赠等方式向公众赠送处方药或者甲类非处方药。不得在大众媒体或门店内外违规发布处方药广告。

第四、加强对高风险药品的管理。对药品零售企业经营销售生物制品(含血液制品)等高风险药品的,在药品采购、储存、销售、运输等环节要严格执行《药品经营质量管理规范》有关规定,采取有效的控制措施,保证药品质量,并确保来源可查,去向可追。

《通知》要求,企业需认真落实执业药师在岗履职。

销售处方药执业药师必须在岗,并严格按照业务规范对处方进行审核、签字后调配、销售;执业药师不在岗,应当挂牌告知,并停止销售处方药。其他允许销售的处方药,应当索取处方,凭处方销售。处方和处方药登记销售记录应当保存2年备查。

顾客不能提供处方的,可以在执业药师或“经确认的从业药师”的指导下,凭购药者病历上的医嘱登记销售,并认真填写全省统一的“处方药销售登记表”,完善销售处方药的具体品种名称、批号、数量、时间等信息。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687328, encodeId=2918168e328fe, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Mar 17 00:23:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724752, encodeId=848a1e24752f3, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Mon Jul 22 22:23:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301646, encodeId=732c13016466f, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345976, encodeId=3d3413459e695, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361048, encodeId=aed036104889, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Feb 19 22:30:24 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687328, encodeId=2918168e328fe, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Mar 17 00:23:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724752, encodeId=848a1e24752f3, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Mon Jul 22 22:23:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301646, encodeId=732c13016466f, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345976, encodeId=3d3413459e695, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361048, encodeId=aed036104889, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Feb 19 22:30:24 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687328, encodeId=2918168e328fe, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Mar 17 00:23:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724752, encodeId=848a1e24752f3, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Mon Jul 22 22:23:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301646, encodeId=732c13016466f, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345976, encodeId=3d3413459e695, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361048, encodeId=aed036104889, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Feb 19 22:30:24 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
    2019-02-21 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687328, encodeId=2918168e328fe, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Mar 17 00:23:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724752, encodeId=848a1e24752f3, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Mon Jul 22 22:23:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301646, encodeId=732c13016466f, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345976, encodeId=3d3413459e695, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361048, encodeId=aed036104889, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Feb 19 22:30:24 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687328, encodeId=2918168e328fe, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sun Mar 17 00:23:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724752, encodeId=848a1e24752f3, content=<a href='/topic/show?id=84c5458013c' target=_blank style='color:#2F92EE;'>#安徽省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45801, encryptionId=84c5458013c, topicName=安徽省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=894533672038, createdName=charl1234578, createdTime=Mon Jul 22 22:23:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301646, encodeId=732c13016466f, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345976, encodeId=3d3413459e695, content=<a href='/topic/show?id=07538e56244' target=_blank style='color:#2F92EE;'>#药店#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87562, encryptionId=07538e56244, topicName=药店)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Feb 21 13:23:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361048, encodeId=aed036104889, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Feb 19 22:30:24 CST 2019, time=2019-02-19, status=1, ipAttribution=)]
    2019-02-19 smartxiuxiu

    0

相关资讯

消费者称去买医生开的处方药被推荐换药,药店:考虑其经济性

李先生的父亲患高血压,并且肾功能不全,医生建议其使用一款名为“安博维”厄贝沙坦的药物。不过其母亲去药房买药时,却被店员推荐并购买了另外一种处方药。值得注意的是,这个药的禁忌中就包括“严重肾功能不良患者”,药品毛利率也高出安博维30%。店员称,自己只是为了病人长期用药的经济性,并没有想到药品利润方面。另一方面,买药过程中李先生的母亲都没带处方。目前,锦江区市场与质量监督管理局正在处理该事件。店员解

新规出台!处方药、特医食品全网限禁?

近日,笔者从国家发改委官网获悉,2018版的《市场准入负面清单》正式发布实施,处方药与特医食品双双上榜,被列为“禁止准入类”项目。这一由国家发改委和商务部主抓的新规正式落地出台后或将让药店药房、网上药店等药品、特医食品经营企业重新洗牌,这些生产经营企业是转行还是转型?互联网医院开具出售处方药是否受限?共同探讨、细读政策文件背后的禁售周期与时长......大势已定:处方药、特医食品禁止准入,全网禁售

Brit J Sport Med:首次!科学家证明运动可能和处方药有着相同的降血压效果

运动有助于降低血压很多人都知道。但是,对于大多高血压患者来说,运动到底能不能取代吃药呢?这或许是他们比较感兴趣的一个问题。

医保带量采购挤压处方药零售

随着医保带量采购的推开,部分分析认为处方药开发零售市场将成为下一步发展的重点。但从市场趋势来看,医院内药价断崖式下跌将对药品零售市场形成很大的冲击,尤其是对寄希望于处方外流的零售渠道形成较大的影响,零售市场很难成为高价原研药和其他仿制药的救命稻草。

Br J Gen Pract:英研究称,三分之一患者合用西药和中草药或保健品,或有危险

一项研究估计,英国约有超过100万65岁以上的人在服用处方药物的同时,还服用中草药和保健品,这些中草药和保健品与药物相互作用,可能会产生危险的副作用。

Int J Geriatr Psych:处方药滥用增加老人自杀风险

在一项针对美国老年人的研究中发现滥用处方类药物阿片或抗焦虑镇静药物(如赞安诺)与自杀意念相关。